Armata Pharmaceuticals
ARMP
Armata Pharmaceuticals (ARMP) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.45
- EPS estimate
- −$0.39
- EPS surprise
- −15.38%
- Revenue surprise
- +57.17%
- Revenue
- $2.2M
- Revenue estimate
- $1.4M
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.39 | −$0.45 | −15.38% | $2.2M | SEC |
| Q1 2025 | May 14, 2025 | −$0.38 | −$0.20 | +47.37% | $491,000.00 | SEC |
| Q4 2024 | Mar 21, 2025 | −$0.35 | −$0.23 | +34.29% | $1.2M | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.28 | −$0.15 | +46.43% | $3.0M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.37 | −$0.25 | +32.43% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.31 | −$0.69 | −122.58% | $966,000.00 | SEC |
| Q4 2023 | Mar 21, 2024 | −$0.29 | −$0.55 | −92.98% | $1.5M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.26 | −$0.86 | −237.25% | $1.2M | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.30 | −$0.17 | +42.37% | $980,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$0.25 | −$0.40 | −60.00% | $796,000.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$0.22 | −$0.29 | −34.88% | $1.1M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.22 | −$0.24 | −9.09% | $1.3M | — |
| Q2 2022 | Aug 11, 2022 | −$0.19 | −$0.26 | −36.84% | $1.9M | — |
| Q1 2022 | May 12, 2022 | −$0.17 | −$0.30 | −81.82% | $1.2M | — |
| Q4 2021 | Mar 17, 2022 | −$0.24 | −$0.23 | +4.17% | $989,000.00 | — |
| Q3 2021 | Nov 10, 2021 | −$0.23 | −$0.22 | +5.70% | $1.3M | — |
| Q2 2021 | Aug 12, 2021 | −$0.21 | −$0.25 | −21.95% | $1.2M | — |
| Q1 2021 | May 13, 2021 | −$0.24 | −$0.27 | −14.89% | $1.1M | — |
| Q4 2020 | Mar 18, 2021 | −$0.10 | −$0.36 | −269.23% | $504,000.00 | — |
| Q3 2020 | Nov 12, 2020 | −$0.20 | −$0.31 | −52.48% | $288,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Armata Pharmaceuticals (ARMP) last report earnings?
Armata Pharmaceuticals last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did ARMP beat earnings estimates?
No. Armata Pharmaceuticals reported EPS of −$0.45 for Q2 2025 against a −$0.39 estimate — a 15.38% miss.
How much revenue did ARMP report last quarter?
Armata Pharmaceuticals reported $2.2M in revenue for Q2 2025, against a consensus estimate of $1.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.